Fentanyl citrate

Under development - samples available

Under development - samples are available

Commercially available

This API is part of the FCC product portfolio and is available for selected markets only

This API is part of the FCC product portfolio and is available for selected markets only

This API is part of the FCC product portfolio and is available for selected markets only 

This API is part of the FCC product portfolio and is available for selected markets only

This API is part of the FCC product portfolio and is available for selected markets only

Aspen Oss B.V offers a wide range of high quality APIs. Chorionic Gonadotrophin is part of our biochemical portfolio. Key characteristics of Chorionic Gonadotrophin are: • Dedicated facilities and equipment for extraction and purification • Full quality oversight, control and traceability through our exte...

Aspen Oss B.V offers a wide range of products which includes heparin sodium. Contact us for more information.

Desmopressin is part of our peptide portfolio. All our APIs are produced routinely and on commercial scale according to cGMP.Aspen Oss has 50 years of peptide experience. We have a batch to batch reproducibility combined with high yield and purify profiles.

Gonadorelin acetate is part of our peptide portfolio. All our APIs are produced routinely and on commercial scale according to cGMP.

Aspen Oss has 50 years of peptide experience. We have a batch to batch reproducibility combined with high yield and purify profiles.

Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 

Aspen is a global specialty and branded pharmaceutical company committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.

Panel at CPHI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency